Fluoxetine: A review of its use in women's health

CNS Drugs

Volumn 14, Issue 4, 2000, Pages 301-328

  Simpson, K ^a   Noble, S ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE;

ANOREXIA NERVOSA; BODY WEIGHT; BULIMIA; COUNSELING; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; EATING DISORDER; HUMAN; POSTMENOPAUSE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC TRANSMISSION;

EID: 0033786768     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200014040-00005     Document Type: Review

References (189)

1. Practical psychopharmacologic considerations in depression
2. Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness
3. Fluoxetine: A review of its use in anxiety disorders and mixed anxiety and depression
4. Fluoxetine: An overview of its pharmacodynamic and pharmacokinetic properties and review of its therapeutic efficacy in obsessive-compulsive disorder
5. Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
6. Fluoxetine: A pharmacoeconomic review of its use in depression
7. Managed care approaches and models for the treatment and management of depression: Specific issues for women
8. Fluoxetine vs. tricyclic antidepressants in women with major depressive disorder
9. Depression in women - ACOG technical bulletin number 182
10. Epidemiology of depressive mood in adolescents: An empirical study
11. Six-month prevalence of psychiatric disorders in three communities 1980-1982
12. Sex and depression in the National Comorbidity Survey: I. Lifetime prevalence, chronicity and recurrence
13. A 40-year perspective on the prevalence of depression: The Stirling County Study
14. Pharmacologic treatment of depression in women: PMS, pregnancy, and the postpartum period
15. Characteristics of menopausal women seeking assistance
16. Postnatal depression
17. Eating disorders
18. Eating disorders
19. Neurochemical abnormalities of anorexia nervosa and bulimia nervosa
20. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa
21. CSF 5-HIAA concentratrions in anorexia nervosa: Reduced values in underweight subjects normalized after weight gain
22. Advances in the diagnosis and treatment of premenstrual dysphoria
23. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria
24. Antidepressants in the treatment of premenstrual dysphoric disorder
25. Premenstrual syndromes
26. Acute tryptophan depletion aggravates premenstrual syndrome
27. Fluoxetine: A review of receptor functional effects and their clinical implications
28. Effect of fluoxetine on food intake of humans living in a residential laboratory
29. Fluoxetine increases resting energy expenditure and basal body temperature in humans
30. Drug-nutrient interactions: Inhibition of amino acid intestinal absorption by fluoxetine
31. Comparative behavioural toxicity of the selective serotonin reuptake inhibitors
32. The behavioural toxicity of the selective serotonin reuptake inhibitors
33. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance
34. Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers
35. Effects of serotonin reuptake inhibitors on haemostasis
36. Fluoxetine and hemostatic function: A pilot study
37. Effect of fluoxetine on prothrombin time
38. Study of haemostasis in depressive patients treated with fluoxetine
39. Clinical pharmacokinetics of fluoxetine
40. Pharmacokinetics of second generation antidepressants: Fluoxetine
41. Targeted pharmacotherapy in depression management: Comparative pharmacokinetics of fluoxetine, paroxetine and sertraline
42. Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance
43. Fluoxetine: Clinical pharmacology and physiologic disposition
44. Human cytochromes mediating N-demethylation of fluoxetine in vitro
45. Identification of cytochrome P450 isoforms involved in fluoxetine N-demethylation by C-DNA expressed enzymes
46. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin
47. Translational pharmacokinetics: Current issues with newer antidepressants
48. Gender differences in depression and antidepressant pharmacokinetics and adverse events
49. Sex differences in fluoxetine pharmacokinetics
50. Pharmacokinetic changes during pregnancy and their clinical relevance
51. Follicular and late luteal phase serum fluoxetine levels in women suffering from late luteal phase dysphoric disorder
52. Distribution and excretion of fluoxetine and norfluoxetine in human milk
53. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk
54. Fluoxetine in breast-milk and developmental outcome of breast-fed infants
55. Possible association between fluoxetine hydrochloride and colic in an infant
56. Antidepressant treatment during breast-feeding
57. Fluoxetine disposition and elimination in cirrhosis
58. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function
59. The pharmacokinetics of fluoxetine in elderly subjects
60. Fluoxetine: Age and dose dependent pharmacokinetics and CYP 2C19 inhibition
61. Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa
62. Drug Therapy: Fluoxetine
63. Selective serotonin reuptake inhibitors in affective disorders - II. Efficacy and quality of life
64. A Controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression
65. Fluoxetine treatment of postpartum depression
66. Prevention of recurrent postpartum major depression
67. Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale
68. Fluoxetine efficacy in menopausal women with and without estrogen replacement
69. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial
70. Fluoxetine treatment of premenstrual syndrome [letter]
71. Fluoxetine treatment of premenstrual syndrome
72. Effects of fluoxetine on premenstrual syndrome in chronic headache sufferers
73. Treatment of premenstrual syndrome with fluoxetine: A double-blind, placebo-controlled, crossover study
74. Fluoxetine in the treatment of late luteal phase dysphoric disorder
75. Fluoxetine in the treatment of premenstrual dysphoria
76. Fluoxetine in the treatment of premenstrual dysphoria
77. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder
78. Fluoxetine in the treatment of premenstrual syndrome
79. Fluoxetine's spectrum of action in premenstrual syndrome
80. Fluoxetine in the treatment of premenstrual syndrome
81. Open trial of fluoxetine therapy for premenstrual syndrome
82. Premenstrual dysphoric disorder: Long-term treatment and discontinuation of fluoxetine 20 mg
83. Treatment of premenstrual syndrome with fluoxetine: An open study
84. Long-term fluoxetine treatment of late luteal phase dysphoric disorder
85. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria
86. Single-dose fluoxetine in management of premenstrual syndrome
87. Long-term use of fluoxetine in bulimia nervosa: A retrospective study
88. The fluoxetine treatment of low-weight, chronic bulimia nervosa
89. Fluoxetine and bulimia
90. Fluoxetine as a treatment for bulimia nervosa
91. Fluoxetine and anorexia
92. Effective treatment of bulimia with fluoxetine, a serotonin reuptake inhibitor, in a patient with type I diabetes mellitus
93. Seasonal bulimia treated with fluoxetine and phototherapy
94. Divergent responses to fluoxetine from two compulsive, food-related conditions: Bulimia nervosa and compulsive water drinking
95. Fluoxetine in the treatment of bulimia nervosa: A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group
96. Fluoxetine versus placebo: A double-blind study with bulimic inpatients undergoing intensive psychotherapy
97. Long-term fluoxetine treatment of bulimia nervosa
98. A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: Short-term outcome
99. Intensive nutritional counselling in bulimia nervosa: A role for supplementation with fluoxetine?
100. Long-term treatment of bulimia nervosa following acute response: A comparison of fluoxetine versus placebo [abstract]
101. Fluoxetine in bulimia following failure of psychotherapy
102. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression
103. Medication and psychotherapy in the treatment of bulimia nervosa
104. Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls
105. No effect of adjunctive fluoxetine on eating behavior or weight phobia during the inpatient treatment of anorexia nervosa: An historical case-control study
106. Treatment of an anorexia nervosa patient with fluoxetine
107. Fluoxetine treatment of anorexia nervosa: An open clinical trial
108. An open trial of fluoxetine in patients with anorexia nervosa
109. Does fluoxetine augment the inpatient treatment of anorexia nervosa?
110. Relapse prevention with fluoxetine in anorexia nervosa: A double-blind placebo-controlled study
111. Fluoxetine vs. cognitive behavioral therapy in relapse prevention for anorexia nervosa
112. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. I. Anorexia nervosa - Restricted type
113. Drug safety monitoring of 12 692 patients treated with fluoxetine
114. Adverse events and treatment discontinuations in fluoxetine clinical trials
115. Changes in adverse events reported by patients during 6 months of fluoxetine therapy
116. Prozac: Fluoxetine hydrochloride prescribing information
117. Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria
118. Non-puerperal lactation associated with antidepressant drug use
119. A review of the safety of selective serotonin reuptake inhibitors during pregnancy
120. Outcome of children exposed in utero to fluoxetine: A critical review
121. Predictive value of minor anomalies. I. Association with major malformations
122. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)
123. Birth outcomes in pregnant women taking fluoxetine
124. Effects of first-trimester fluoxetine exposure on the newborn
125. Effects of third trimester fluoxetine exposure on the newborn
126. Treatment of depression during pregnancy
127. Safety of fluoxetine during the first trimester of pregnancy: A meta-analytical review of epidemiological studies
128. Neurodevelopment of children exposed in utero to antidepressant drugs
129. Weight gain in infants breastfed by mothers who take fluoxetine
130. Excretion of fluoxetine in human breastmilk
131. Fluoxetine/norfluoxetine concentrations in human milk
132. Potential fluoxetine chloride (Prozac) toxicity in a newborn
133. Fluoxetine hydrochloride (Prozac) toxicity in a neonate
134. Psychotropic drugs in mothers' milk: A comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding
135. Drug therapy for breast-feeding women
136. Serum concentrations of antidepressants and benzodiazepines in nursing infants: A case series
137. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline
138. Retrospective review of selective serotonin reuptake inhibitor-induced libido disturbance in women
139. Female sexual side effects associated with selective serotonin reuptake inhibitors: A descriptive clinical study of 33 patients
140. Sexual dysfunctioning in users of selective serotonin reuptake inhibitors (SSRIs)
141. Antidepressant-induced sexual dysfunction: A multicenter and prospective study using a questionnaire of 693 patients. American Psychiatric Association
142. The role of serotonin in sexual dysfunction: Fluoxetine-associated orgasm dysfunction
143. Migraine in pregnancy: What are the safest treatment options?
144. The fluoxetine and suicide controversy: A reveiw of the evidence
145. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies
146. Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression
147. Fluoxetine: No association with suicidality in obsessive-compulsive disorder
148. Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects
149. The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders
150. Lack of association between fluoxetine and suicidality in bulimia nervosa
151. Serotonin syndrome: Incidence, symptoms and treatment
152. Fluoxetine withdrawal symptoms
153. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system
154. Selective serotonin reuptake inhibitors and withdrawal symptoms: A review of the literature
155. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial
156. Interruption of selective serotonin reuptake inhibitor treatment
157. Safety of abrupt discontinuation of fluoxetine: A randomized, placebo-controlled study
158. Changes in weight during a 1-year trial of fluoxetine
159. Fluoxetine in depressed geriatric patients: Effect on weight
160. Antidepressants and weight: A comparative study of four antidepressants and their effect on the weight of depressed patients
161. Fluoxetine versus sertraline and paroxetine in major depression: Long-term changes in weight
162. Weight gain during fluoxetine treatment
163. Paradoxical effects of fluoxetine
164. Depression during pregnancy and the puerperium
165. Postpartum psychiatric disorders: Guidelines for management
166. Pregnant or depressed? The effect of overlap between symptoms of depression and somatic complaints of pregnancy on rates of major depression in the second trimester
167. Screening methods for postpartum depression
168. A standardized interview that differentiates pregnancy and postpartum symptoms from perinatal clinical depression
169. A prospective study of emotional disorders in childbearing women
170. Social support, life events and depression during pregnancy and the puerperium
171. Psychological and social correlates of the onset of affective disorders among pregnant women
172. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum
173. Pregnancy-related affective disorders among women with recurrent depression
174. The safety of fluoxetine during pregnancy
175. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines
176. Selective serotonin-reuptake inhibitors in pregnancy and lactation
177. Treating recurrent affective disorders during and after pregnancy: What can be taken safely?
178. The safety of fluoxetine during pregnancy and lactation
179. Selective serotonin reuptake inhibitors in pregnancy and lactation
180. Birth control failure among patients with unwanted pregnancies: 1982-1984
181. Congenital abnormalites in the newborn infant, including minor variations: A study of 4412 babies by surface examination for anomalies and buccal smear for sex chromatin
182. Transdermal oestrogen for treatment of severe postnatal depression
183. Psychotropic medications in lactation
184. A guide top the safety of CNS-active agents during breastfeeding
185. Use of psychotropic medications in breast-feeding women: Acute and prophylactic treatment
186. Hormones and depression: What are the facts about premenstrual syndrome, menopause, and hormone replacement therapy?
187. Premenstrual syndrome: Current perspectives on treatment and etiology
188. Depression and eating disorders